Immuneering
IMRX
42 hedge funds and large institutions have $9.32M invested in Immuneering in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
11% more funds holding
Funds holding: 38 → 42 (+4)
0.83% less ownership
Funds ownership: 14.69% → 13.86% (-0.83%)
14% less capital invested
Capital invested by funds: $10.9M → $9.32M (-$1.55M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rockefeller Capital Management
New York
|
+$368K |
| 2 |
First Manhattan
New York
|
+$67K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$46.4K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$44.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$43.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$473K |
| 2 |
Millennium Management
New York
|
-$297K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$89.2K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$36.9K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$28K |
IMRX Hedge Fund Activity: Q4 2024 in Review
42 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q4 2024, worth a combined $9.32M — down 14% from $10.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new IMRX positions and 3 closed out — a net gain of 4 holders — while 12 added to existing stakes and 10 trimmed.
The largest buyer was Rockefeller Capital Management, opening a new position worth an estimated $368K. The largest seller was Prosight Management, exiting entirely with an estimated $473K sold.
- 42 institutional investors held Immuneering (IMRX) as of Q4 2024, up from 38 in Q3 2024.
- Funds reported $9.32M of Immuneering stock for Q4 2024, down 14% quarter-over-quarter.
- 7 funds opened new Immuneering positions in Q4 2024 and 3 closed out, a net change of +4 holders.
- The largest Immuneering buyer in Q4 2024 was Rockefeller Capital Management, an estimated $368K added.
- The largest Immuneering seller in Q4 2024 was Prosight Management, an estimated $473K sold.
Based on aggregated 13F filings for Q4 2024.